↓ Skip to main content

The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents

Overview of attention for article published in Applied Health Economics and Health Policy, August 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#1 of 485)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news
52 news outlets
blogs
2 blogs
twitter
3 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
3 Mendeley
Title
The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents
Published in
Applied Health Economics and Health Policy, August 2018
DOI 10.1007/s40258-018-0420-8
Pubmed ID
Authors

Jonathan J. Darrow, Reed F. Beall, Aaron S. Kesselheim

Abstract

Most new brand-name drugs are protected by patents from generic competition, but these patents are occasionally granted in error. Invalidating such patents has traditionally been accomplished via court litigation by generic manufacturers, which is expensive and time consuming. In 2011, Congress created an administrative alternative to court litigation of patents, called inter partes review, intended to be much faster and less expensive. To evaluate the use of inter partes review to challenge pharmaceutical patents, including the number of challenges, the number of associated drug products, and the extent to which challengers have been successful. We obtained data pertaining to inter partes review proceedings, including identity of patent challenger, duration of proceedings, and outcome, from September 16, 2012 through April 24, 2017 from UnifiedPatents.com, and combined it with information about drug products and their associated patents, including patent type, contained in the US Food and Drug Administration's Orange Book. Generic drug manufacturers have embraced the new inter partes review process, succeeding in overturning all challenged claims in 43% of the patents they have targeted since 2011, and some challenged claims in an additional 8%. Inter partes review for drug patents has consistently been completed within 12 months, as required by statute. Successful challenges have been brought most frequently against drug patents covering new formulations or methods of use, rather than drug patents covering active ingredients. In the pharmaceutical market, the inter partes review process can meaningfully contribute to ensuring that invalid patents do not block timely availability of generic drugs.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 3 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 3 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 67%
Student > Postgraduate 1 33%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 1 33%
Business, Management and Accounting 1 33%
Agricultural and Biological Sciences 1 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 435. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 October 2018.
All research outputs
#19,498
of 12,761,472 outputs
Outputs from Applied Health Economics and Health Policy
#1
of 485 outputs
Outputs of similar age
#901
of 272,835 outputs
Outputs of similar age from Applied Health Economics and Health Policy
#1
of 13 outputs
Altmetric has tracked 12,761,472 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 485 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 272,835 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.